No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials

Abstract Background Secukinumab is an interleukin (IL)-17 inhibitor approved to treat patients with axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Treatment recommendations highlight the importance of individualized treatment of patients with axSpA...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Sofia Ramiro, Corine Gaillez, Uta Kiltz, Lianne S. Gensler, Chaitali Pisal, Jurgen Braun, Alexis Ogdie
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2026-04-01
Schriftenreihe:	Arthritis Research & Therapy
Schlagworte:	Secukinumab Axial spondyloarthritis Interleukin-17 ASAS ASDAS
Online-Zugang:	https://doi.org/10.1186/s13075-026-03804-y
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!